Tercica (TRCA) is a small biotech which had an operating loss of $86 million last year on revenue of a little over $1 million. The year’s numbers have not been much better.
The company’s shares are up almost 25% after hours to $6.60 which would give the company a market cap over $270 million.
Why? Tercica signed a deal with Genentech (DNA) for the larger company to pay "up to" $53 million "to combine its Increlex with Genentech’s Nutropin, a growth hormone, to form a once-daily injectable treatment for children who don’t grow normally," according to CNN Money.
Phase 2 testing will not begin until next year, so the drug may or may not be approved by 2010.
A lot can happen in three years.
Douglas A. McIntyre
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
